biotech licensing

Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC

INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...

By cGxPwire Editor
June 1, 2026

M&A

Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide

SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...

By cGxPwire Editor
June 1, 2026

M&A

Dogwood Therapeutics Secures $100M Partnership for Antiviral Assets

Alpharetta, Georgia, USA – April 23, 2026 Dogwood Therapeutics announced a global development and commercialization partnership with PRIDCor Therapeutics...

By cGxPwire Editor
April 24, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC

Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide

Dogwood Therapeutics Secures $100M Partnership for Antiviral Assets